Francisco Salvador Pascual1, Alvaro Muñoz2, Rodrigo Oraa3, Gerardo Flórez4, Pilar Notario5, Pedro Seijo6, Begoña Gonzalvo7, Carla Assaf8, Manuel Gómez2, Miguel Ángel Casado2. 1. Generalitat Valenciana, Unidad de Conductas Adictivas, Departament de Sault d'Alcoi, Alcoi, Spain. 2. Outcomes Research, Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain. 3. Red de Salud Mental, Biocruces Bizkaia Health Research Institute, CSM Ajuriaguerra Adicciones, RSMB, Bilbao, Spain. 4. Servizo Galego de Saúde, Unidad de Conductas Adictivas de Ourense, Ourense, Spain. 5. Subdirección General de Adicciones, Centro de Atención a las Adicciones de Latina, Madrid, Spain. 6. Diputación de Cádiz, Centro de Tratamiento Ambulatorio de Adicciones de Villamartín, Cádiz, Spain. 7. Red Adicciones, Institut Assistència Sanitària, Departament de Salut Centro de Atención y Seguimiento a las Drogodependencias, Girona, Spain. 8. Medical Department, Camurus SL, Madrid, Spain.
Abstract
AIM: The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). METHODS: This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. RESULTS: A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; p = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; p = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; p < 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; p = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; p = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; p = 0.833). The main reason was administration by injection. CONCLUSION: Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management. The Author(s). Published by S. Karger AG, Basel.
AIM: The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). METHODS: This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. RESULTS: A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; p = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; p = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; p < 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; p = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; p = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; p = 0.833). The main reason was administration by injection. CONCLUSION: Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management. The Author(s). Published by S. Karger AG, Basel.
Authors: John Strang; Kylie Reed; Karolina Bogdanowicz; James Bell; Rob van der Waal; Jenny Keen; Pete Beavan; Shelagh Baillie; Alastair Knight Journal: Eur Addict Res Date: 2017-03-08 Impact factor: 3.015
Authors: Louisa Degenhardt; Harvey A Whiteford; Alize J Ferrari; Amanda J Baxter; Fiona J Charlson; Wayne D Hall; Greg Freedman; Roy Burstein; Nicole Johns; Rebecca E Engell; Abraham Flaxman; Christopher J L Murray; Theo Vos Journal: Lancet Date: 2013-08-29 Impact factor: 79.321
Authors: Maurice Dematteis; Marc Auriacombe; Oscar D'Agnone; Lorenzo Somaini; Néstor Szerman; Richard Littlewood; Farrukh Alam; Hannu Alho; Amine Benyamina; Julio Bobes; Jean Pierre Daulouede; Claudio Leonardi; Icro Maremmani; Marta Torrens; Stephan Walcher; Michael Soyka Journal: Expert Opin Pharmacother Date: 2017-12-03 Impact factor: 3.889
Authors: Carlos Roncero; Raquel Domínguez-Hernández; Tomás Díaz; José Manuel Fernández; Rafael Forcada; José Manuel Martínez; Pedro Seijo; Antonio Terán; Itziar Oyagüez Journal: Adicciones Date: 2015-09-15 Impact factor: 2.979
Authors: Briony Larance; Louisa Degenhardt; Jason Grebely; Suzanne Nielsen; Raimondo Bruno; Paul Dietze; Kari Lancaster; Sarah Larney; Thomas Santo; Marian Shanahan; Sonja Memedovic; Robert Ali; Michael Farrell Journal: Addiction Date: 2020-02-05 Impact factor: 6.526